Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa metabolic balance study of FE 203799 in short bowel syndrome
2017-002487-41Phase 2Completed
- Sponsor
- GLyPharma
- Start
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apraglutide in short bowel syndrome (SBS), sponsored by GLyPharma. Primary endpoint: Safety and tolerability. Started Dec 2017; status: completed.
02
Drugs
apraglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2017-002487-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002487-41.